MNKD Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
MannKind Corp (MNKD) is not a strong buy at this time for a beginner investor with a long-term focus. The stock is currently facing significant uncertainties regarding its future revenue streams, particularly due to risks surrounding Tyvaso DPI royalties and competition from United Therapeutics' soft mist inhaler. While the technical indicators suggest the stock is oversold, the lack of positive trading signals, weak financial performance, and bearish sentiment from hedge funds and analysts make it prudent to hold off on investing at this time.
The MACD is positive and expanding, suggesting a potential bullish momentum. However, the RSI indicates the stock is oversold at 14.716. Moving averages are bearish (SMA_200 > SMA_20 > SMA_5), and the stock is trading near its support level of 2.299, with resistance at 2.773. Overall, the technical setup is mixed, with no clear buy signal.
The company reported a 45.82% YoY increase in revenue for Q4 2025, indicating strong top-line growth. Analysts see potential upside if MannKind can execute on its internal 2026 catalysts, such as FDA decisions on Afrezza label updates and pediatric use applications.
Significant risks to future revenue streams due to United Therapeutics' development of a competing soft mist inhaler. Hedge funds are selling aggressively, with a 337.78% increase in selling activity. Analysts have lowered price targets significantly, with some downgrading the stock due to uncertainties surrounding Tyvaso DPI royalties.
In Q4 2025, revenue increased by 45.82% YoY to $111.96M. However, net income dropped by -314.87% YoY to -$15.95M, and EPS fell to -$0.05, down -266.67% YoY. Gross margin also declined to 71.82%, down -6.81% YoY. Overall, the financial performance reflects strong revenue growth but worsening profitability.
Analysts are mixed but leaning bearish. Several firms have lowered price targets recently, citing risks to Tyvaso DPI royalties and competition from United Therapeutics. Current price targets range from $3.50 to $11, with most analysts maintaining Buy or Outperform ratings but acknowledging significant risks in the near term.
